Ruane, Cunniff & Goldfarb’s Bristol-Myers Squibb BMY Stock Holding History

Ruane, Cunniff & Goldfarb’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,670	Closed	-$252K	–	136
2015 Q4	$252K	Hold	3,670	–	–	﹤0.01%	139
2015 Q3	$217K	Hold	3,670	–	–	﹤0.01%	144
2015 Q2	$244K	Hold	3,670	–	–	﹤0.01%	139
2015 Q1	$237K	Hold	3,670	–	–	﹤0.01%	144
2014 Q4	$217K	Buy	+3,670	New	+$207K	﹤0.01%	148

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ruane, Cunniff & Goldfarb's BMY Position: Q1 2016 in Review

Ruane, Cunniff & Goldfarb sold out of Bristol-Myers Squibb (BMY) in Q1 2016, closing a stake of 3,670 shares — an estimated $252K sold.

Ruane, Cunniff & Goldfarb first reported a position in BMY in Q4 2014 and held it in 5 quarters. The position peaked at $252K in Q4 2015. 1,523 funds tracked by Wall St. Rank hold BMY as of Q1 2016.

Ruane, Cunniff & Goldfarb reported no remaining Bristol-Myers Squibb position as of Q1 2016 after selling out during the quarter.
Ruane, Cunniff & Goldfarb sold 3,670 Bristol-Myers Squibb shares in Q1 2016, an estimated $252K.
Ruane, Cunniff & Goldfarb first reported a position in Bristol-Myers Squibb in Q4 2014 and held it in 5 quarters.
Ruane, Cunniff & Goldfarb's Bristol-Myers Squibb position peaked at $252K in Q4 2015.
1,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2016.

Based on Ruane, Cunniff & Goldfarb's 13F filing for Q1 2016, filed 16 May 2016.